Latest From Biotech Now

India’s IP Policy: India’s Lead Biotech Innovator Expresses Concern

shutterstock_2103563

Kiran Mazumdar-Shaw, chairperson and managing director of India’s largest biotechnology company Biocon, expressed concern with India’s innovation environment in a recent interview with Livemint.  When asked if the Indian government fosters innovation Ms. Shaw responded: “I am very concerned about the wrong signals we are sending to the world. We have not done anything substantial to build India as a strong global economy. We have wasted a lot of opportunities. We behave like the world Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BioCentury This Week: Death & Taxes – Startups Need Fixes

BioCenturyTV

Vitae CEO Jeff Hatfield, Ernst & Young Partner Christopher Ohmes, and GPB Scientific CEO Michael Grisham will be discussing proposed tax changes that could spur billions of dollars in investment and create hundreds of thousands of jobs on BioCentury This Week airing Sunday September, 15 at 8:30am EST on WUSA-9. Biotech startups face death before taxes and unless investors are willing to finance years of losses, technologies that could save and improve lives are left Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

“Let’s Take Advantage of It,” Biotech in the US-EU Trade Agreement

admin-ajax

As the second round of the Transatlantic Trade and Investment Partnership (TTIP) talks approach Brussels in October, several noteworthy articles remind us why biotech is such an important driving force in these discussions. Dean Kleckner, chairman emeritus for Truth About Trade & Technology (TATT), in recent articles in the Washington Times and Des Moines Register wrote a piece titled “Ending Flaky Trade Barriers,” highlighting challenges within the US-EU trade agreement and illustrating why biotech should Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

12th Annual BIO Investor Forum Presenting Companies Announced

San Francisco skyline

Looking to lose a few pounds? Don’t want to diet or exercise? You’re not alone: fully one-third of Americans are obese, and many companies are trying to discover the first blockbuster diet drug and make a dent in the obesity epidemic. We’ll hear from one of those companies next month at the 12th Annual BIO Investor Forum, taking place October 8-9th in San Francisco. Cambridge-based Zafgen is hoping to bring to market their first-in-class obesity Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,